Drug Profile
Research programme: NR2B NMDA receptor negative allosteric modulators - BioCrea
Alternative Names: NR2B NAMs - BioCreaLatest Information Update: 28 Feb 2018
Price :
$50
*
At a glance
- Originator biocrea GmbH
- Class Small molecules
- Mechanism of Action NR2B N-Methyl D-Aspartate receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Depressive disorders; Major depressive disorder
Most Recent Events
- 28 Feb 2018 No recent reports of development identified for research development in Depressive disorders(Treatment-resistant) in Germany
- 28 Feb 2018 No recent reports of development identified for research development in Major depressive disorder(Treatment-resistant) in Germany
- 23 Apr 2014 BioCrea is actively seeking to out-license or partner its NR2B NMDA receptor negative allosteric modulators programme as of 23 Apr 2014. http://www.biocrea.com